Mast cell tumors (MCTs) are the most common form of skin cancer in dogs (16 to 21% of skin tumors¹), and most often result in a nodule under or on the surface of the skin. Treatments such as chemotherapy, radiation and surgery exist, but they are not always possible or appropriate to the animal's specific case. They also involve either repeated use of medication or anesthesia that is potentially worrisome to the pet owner or contraindicated for the animal. 

Through a collaboration with QBiotics, we are providing a breakthrough injectable solution to treat non-metastatic skin-based (cutaneous) mast cell tumors in dogs. Progressively made available to European veterinarians throughout 2020, it will also soon be available to North American veterinarians following FDA approval on November 16. With this new intratumoral treatment, Virbac once again demonstrates its commitment and ability to offer unique solutions for the advancement of veterinary medicine.

Sophie Favini, Executive Vice President US Commercial Operations at Virbac Corporation: "At Virbac, we are very proud that the fruitful collaboration with Qbiotics enables us to bring this breakthrough to the US veterinary oncologists and general practitioners. Our new solution will allow them to propose a less invasive and less risky alternative to surgery. This will, for sure be well received by pet owners, always keen to avoid anesthesia for their pets.”

For more information, on the website Virbac U.S. 

^{1- Bostock DE. Neoplasms of the skin and subcutaneous tissues in dogs and cats. Br Vet.J 1986; 142: 1-19. Dobson JM, Samuel S, Milstein H, et al. Canine neoplasia in the UK: estimates of incidence rates from a population of insured dogs. J Small Anim Pract 2002;43:240–246.}

GO BACK